Pharmacolog i Uppsala AB (publ) announces that the publication of the interim report for the second quarter is brought forward and will be published on 12 August 2021.
The advance is because the subscription period for the outstanding warrants takes place during the mandatory silent period that exists 30 days before the publication of the half-year report. This means that insiders on the board and management are prevented from exercising their warrants. As there is great interest among the Board and management to exercise their warrants, the company has decided to bring forward the publication of the half-year report. It will be published on Thursday, August 12, 2021. The previously announced date of publication was August 27, 2021.
For more information contact:
Mats Högberg, CEO
Phone: +46 70-546 50 21
About Pharmacolog AB
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.